|
Second Phase of Rollout Builds on Strong Momentum Across Europe and UK.
ROCHESTER, N.Y., March 2, 2026 /PRNewswire/ -- CooperVision is continuing its global rollout of MyDay® MiSight® 1 day contact lenses with immediate availability in Australia and New Zealand, marking the myopia control product's first entry into the Asia Pacific region. In addition, the innovative lenses are now shipping in South Africa and Israel, building on the initial launch earlier this year across Europe, the Middle East and Africa.
The expansions underscore the company's commitment to making evidence-based myopia management interventions accessible to eye care professionals (ECPs) and children worldwide.
"Myopia is a pressing health challenge of epic proportions, now affecting nearly one in three children worldwide," said Debbie Olive, Chief Commercial Officer for CooperVision.*1,2,3 "The growing availability and adoption of our myopia control contact lenses, including MyDay® MiSight® 1 day, are helping drive a meaningful shift in pediatric eye care by supporting children's vision today while helping protect their sight for the future."
MyDay® MiSight® 1 day combines the proven MiSight® 1 day ActivControl® Technology with the advanced silicone hydrogel material used in MyDay® lenses, offering "always-on" myopia control alongside the comfort and performance of a daily disposable silicone hydrogel lens.†4 This technology has demonstrated an approximate 50% reduction in myopia progression and is supported by the longest-running soft contact lens clinical trial for myopia control in children. ‡5,6
"The introduction of MyDay® MiSight® 1 day into the Asia Pacific region marks an important milestone in our global efforts to make the latest in evidence-based myopia control accessible to as many children as possible," said Jennifer Lambert, VP – Myopia Control & Cornea Care for CooperVision, CooperVision. "As MiSight® products become available in more markets worldwide, CooperVision's scale and focus are driving a shift in the paradigm, from simply correcting vision to actively controlling myopia progression."
CooperVision expects to continue its phased MyDay® MiSight® 1 day expansion in the coming months, including additional availability in Asia Pacific markets.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over 50 million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
_________________________________
* Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
† Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.
‡ Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day.
_________________________________
1 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2 Liang J, Pu Y, Chen J, et al, Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis, British Journal of Ophthalmology 2025;109:362-371.
3 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
4 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
5 Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
6 CVI data on file, 2025.
Photo - https://mma.prnasia.com/media2/2922809/CooperVision_MyDay_MiSight_1_day.jpg?p=medium600
Logo - https://mma.prnewswire.com/media/2854596/5829336/CooperVision_Logo.jpg
Second Phase of Rollout Builds on Strong Momentum Across Europe and UK.
ROCHESTER, N.Y., March 2, 2026 /PRNewswire/ -- CooperVision is continuing its global rollout of MyDay® MiSight® 1 day contact lenses with immediate availability in Australia and New Zealand, marking the myopia control product's first entry into the Asia Pacific region. In addition, the innovative lenses are now shipping in South Africa and Israel, building on the initial launch earlier this year across Europe, the Middle East and Africa.
The expansions underscore the company's commitment to making evidence-based myopia management interventions accessible to eye care professionals (ECPs) and children worldwide.
"Myopia is a pressing health challenge of epic proportions, now affecting nearly one in three children worldwide," said Debbie Olive, Chief Commercial Officer for CooperVision.*1,2,3 "The growing availability and adoption of our myopia control contact lenses, including MyDay® MiSight® 1 day, are helping drive a meaningful shift in pediatric eye care by supporting children's vision today while helping protect their sight for the future."
MyDay® MiSight® 1 day combines the proven MiSight® 1 day ActivControl® Technology with the advanced silicone hydrogel material used in MyDay® lenses, offering "always-on" myopia control alongside the comfort and performance of a daily disposable silicone hydrogel lens.†4 This technology has demonstrated an approximate 50% reduction in myopia progression and is supported by the longest-running soft contact lens clinical trial for myopia control in children. ‡5,6
"The introduction of MyDay® MiSight® 1 day into the Asia Pacific region marks an important milestone in our global efforts to make the latest in evidence-based myopia control accessible to as many children as possible," said Jennifer Lambert, VP – Myopia Control & Cornea Care for CooperVision, CooperVision. "As MiSight® products become available in more markets worldwide, CooperVision's scale and focus are driving a shift in the paradigm, from simply correcting vision to actively controlling myopia progression."
CooperVision expects to continue its phased MyDay® MiSight® 1 day expansion in the coming months, including additional availability in Asia Pacific markets.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over 50 million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
_________________________________
* Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
† Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.
‡ Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day.
_________________________________
1 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2 Liang J, Pu Y, Chen J, et al, Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis, British Journal of Ophthalmology 2025;109:362-371.
3 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
4 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
5 Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
6 CVI data on file, 2025.
Photo - https://mma.prnasia.com/media2/2922809/CooperVision_MyDay_MiSight_1_day.jpg?p=medium600
Logo - https://mma.prnewswire.com/media/2854596/5829336/CooperVision_Logo.jpg
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region
|
The new MyLab™E85 GTS and MyLab™C30 GTS Edition ultrasound systems will be presented on Thursday, 5th March at 11.30 a.m. at the Esaote Booth
GENOA, Italy, March 2, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging – ultrasound, dedicated magnetic resonance and medical IT – attends European Congress of Radiology 2026 in Vienna (March 4-8, Booth 505 Expo Hall X5) with a renewed commitment to supporting radiologists in delivering accurate diagnoses and improved patient outcomes.
At ECR 2026, Esaote places particular emphasis on ultrasound innovation for interventional radiology, reinforcing its dedication to ultrasound-guided procedures and therapies (GTS) where precision and confidence are essential. This commitment takes shape with the official launch of the new MyLab™E85 and MyLab™C30 GTS Edition ultrasound systems that will be held on Thursday, 5th March at 11.30 a.m. at Esaote booth.
"With these new ultrasound systems, our goal is to give interventional Radiologists the most reliable and intuitive tools to support every phase of their procedures," says Marta Daniel, GTS Product and Clinical Solutions Manager at Esaote. "MyLab™E85GTS offers advanced imaging technologies for precise diagnosis, excellent needle visualization, and enhanced interventional guidance through Virtual Navigator and exclusive built-in Ablation Confirmation Suite. Virtual Navigator enables real-time multimodality fusion imaging for accurate navigation, which combined with the Ablation Suite for treatment verification, strengthens ultrasound as a reliable adjunct to CT-guided interventions. MyLab™C30GTS reinforces the GTS solutions, providing outstanding imaging and flexibility across clinical environments in a premium compact system, delivering contrast-enhanced, shear-wave elastography and attenuation imaging modes in a portable unit for the first time."
In the field of MRI, Esaote introduces two major innovations at ECR 2026, reinforcing its vision of intelligent, high-performance, and clinically driven MRI: HyperSpeed, a new AI module that significantly accelerates MRI scan times while preserving excellent image quality, and M-Score, a quantitative software solution enabling a bone-health assessment through opportunistic screening during routine lumbar spine MRI exams, will be at the centre of the Workshop "Beyond Images: Driving Clinical Value in MRI through AI technologies," taking place on Friday, March 6, from 12:00 to 13:00 at ECR (Room 1.15, Level 1), led by Francesco Arrigoni and Federico Bruno from the University of L'Aquila.
Ebit, the Esaote Group company specialized in Healthcare IT, presents the latest evolution of SUITESTENSA for radiology & enterprise imaging, introducing advanced AI-enabled workflow orchestration and enhanced structured reporting fully integrated into daily clinical practice. Designed on a cloud-native architecture, the platform embeds AI and quantitative tools directly within the reporting workflow, supporting radiologists with measurable efficiency gains while preserving full clinical control and data governance.
Esaote Group is a leader in medical imaging (ultrasound, MRI and diagnostic process management software). At the end of 2025, the Group counts 1,300 employees, half of which are based in Italy. With facilities in Genoa and Florence and its own production and research units in Italy and the Netherlands, Esaote is present in over 100 countries worldwide. www.esaote.com
The new MyLab™E85 GTS and MyLab™C30 GTS Edition ultrasound systems will be presented on Thursday, 5th March at 11.30 a.m. at the Esaote Booth
GENOA, Italy, March 2, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging – ultrasound, dedicated magnetic resonance and medical IT – attends European Congress of Radiology 2026 in Vienna (March 4-8, Booth 505 Expo Hall X5) with a renewed commitment to supporting radiologists in delivering accurate diagnoses and improved patient outcomes.
At ECR 2026, Esaote places particular emphasis on ultrasound innovation for interventional radiology, reinforcing its dedication to ultrasound-guided procedures and therapies (GTS) where precision and confidence are essential. This commitment takes shape with the official launch of the new MyLab™E85 and MyLab™C30 GTS Edition ultrasound systems that will be held on Thursday, 5th March at 11.30 a.m. at Esaote booth.
"With these new ultrasound systems, our goal is to give interventional Radiologists the most reliable and intuitive tools to support every phase of their procedures," says Marta Daniel, GTS Product and Clinical Solutions Manager at Esaote. "MyLab™E85GTS offers advanced imaging technologies for precise diagnosis, excellent needle visualization, and enhanced interventional guidance through Virtual Navigator and exclusive built-in Ablation Confirmation Suite. Virtual Navigator enables real-time multimodality fusion imaging for accurate navigation, which combined with the Ablation Suite for treatment verification, strengthens ultrasound as a reliable adjunct to CT-guided interventions. MyLab™C30GTS reinforces the GTS solutions, providing outstanding imaging and flexibility across clinical environments in a premium compact system, delivering contrast-enhanced, shear-wave elastography and attenuation imaging modes in a portable unit for the first time."
In the field of MRI, Esaote introduces two major innovations at ECR 2026, reinforcing its vision of intelligent, high-performance, and clinically driven MRI: HyperSpeed, a new AI module that significantly accelerates MRI scan times while preserving excellent image quality, and M-Score, a quantitative software solution enabling a bone-health assessment through opportunistic screening during routine lumbar spine MRI exams, will be at the centre of the Workshop "Beyond Images: Driving Clinical Value in MRI through AI technologies," taking place on Friday, March 6, from 12:00 to 13:00 at ECR (Room 1.15, Level 1), led by Francesco Arrigoni and Federico Bruno from the University of L'Aquila.
Ebit, the Esaote Group company specialized in Healthcare IT, presents the latest evolution of SUITESTENSA for radiology & enterprise imaging, introducing advanced AI-enabled workflow orchestration and enhanced structured reporting fully integrated into daily clinical practice. Designed on a cloud-native architecture, the platform embeds AI and quantitative tools directly within the reporting workflow, supporting radiologists with measurable efficiency gains while preserving full clinical control and data governance.
Esaote Group is a leader in medical imaging (ultrasound, MRI and diagnostic process management software). At the end of 2025, the Group counts 1,300 employees, half of which are based in Italy. With facilities in Genoa and Florence and its own production and research units in Italy and the Netherlands, Esaote is present in over 100 countries worldwide. www.esaote.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
ECR 2026: Esaote Group Introduces Breakthroughs in Ultrasound, MRI and Enterprise Imaging
